• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Cost-effectiveness of rivaroxaban plus aspirin (dual pathway inhibition) for prevention of ischaemic events in patients with cardiovascular disease: on top optimisation of secondary prevention medication in the context of COVID-19 pandemia.

作者信息

Rauch Bernhard

机构信息

IHF - Institut für Herzinfarktforschung Ludwigshafen, Germany.

出版信息

Eur J Prev Cardiol. 2020 Sep;27(13):1351-1353. doi: 10.1177/2047487320920754. Epub 2020 Apr 17.

DOI:10.1177/2047487320920754
PMID:32301349
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7717238/
Abstract
摘要

相似文献

1
Cost-effectiveness of rivaroxaban plus aspirin (dual pathway inhibition) for prevention of ischaemic events in patients with cardiovascular disease: on top optimisation of secondary prevention medication in the context of COVID-19 pandemia.利伐沙班联合阿司匹林（双途径抑制）预防心血管疾病患者缺血性事件的成本效益：在2019冠状病毒病大流行背景下优化二级预防用药之上
Eur J Prev Cardiol. 2020 Sep;27(13):1351-1353. doi: 10.1177/2047487320920754. Epub 2020 Apr 17.
2
Primary and Secondary Prevention of Cardiovascular Disease in the Era of the Coronavirus Pandemic.新冠疫情时代心血管疾病的一级和二级预防
Circulation. 2020 Jun 16;141(24):1943-1945. doi: 10.1161/CIRCULATIONAHA.120.047194. Epub 2020 Apr 20.
3
Early de-escalation of DAPT after PCI: implications of the latest randomized trials in the COVID era.PCI术后双联抗血小板治疗的早期降阶梯：COVID时代最新随机试验的意义
Indian Heart J. 2020 May-Jun;72(3):209-211. doi: 10.1016/j.ihj.2020.05.009. Epub 2020 May 23.
4
The Novel Coronavirus Disease (COVID-19) and Its Impact on Cardiovascular Disease.新型冠状病毒病（COVID-19）及其对心血管疾病的影响。
Cardiol Rev. 2020 Jul/Aug;28(4):163-176. doi: 10.1097/CRD.0000000000000317.
5
Utilization and Appropriateness of Transthoracic Echocardiography in Response to the COVID-19 Pandemic.经胸超声心动图在应对2019冠状病毒病大流行中的应用与适宜性
J Am Soc Echocardiogr. 2020 Jun;33(6):690-691. doi: 10.1016/j.echo.2020.04.006. Epub 2020 Apr 10.
6
An Acute Respiratory Infection Runs Into the Most Common Noncommunicable Epidemic-COVID-19 and Cardiovascular Diseases.一种急性呼吸道感染遭遇了最常见的非传染性流行病——新冠肺炎与心血管疾病。
JAMA Cardiol. 2020 Jul 1;5(7):743-744. doi: 10.1001/jamacardio.2020.0934.
7
[Expert consensus on principal of clinical management of patients with severe emergent cardiovascular diseases during the epidemic period of COVID-19].《新型冠状病毒肺炎疫情期间重症急性心血管疾病患者临床管理原则专家共识》
Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Mar 24;48(3):189-194. doi: 10.3760/cma.j.cn112148-20200210-00066.
8
Fear of Coronavirus Disease 2019-An Emerging Cardiac Risk.对2019冠状病毒病的恐惧——一种新出现的心脏风险。
JAMA Cardiol. 2020 Sep 1;5(9):981-982. doi: 10.1001/jamacardio.2020.2890.
9
CAPACITY-COVID: a European Registry to determine the role of cardiovascular disease in the COVID-19 pandemic.CAPACITY-COVID：一项欧洲登记研究，旨在确定心血管疾病在新冠疫情中的作用。
Eur Heart J. 2020 May 14;41(19):1795-1796. doi: 10.1093/eurheartj/ehaa280.
10
Comparison of cardiovascular metabolic characteristics and impact on COVID-19 and MERS.心血管代谢特征比较及其对新冠病毒病和中东呼吸综合征的影响
Eur J Prev Cardiol. 2020 Aug;27(12):1320-1324. doi: 10.1177/2047487320925218. Epub 2020 May 18.

引用本文的文献

1
Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective.从进化角度看血管防御、止血、癌症和血小板生物学。
Cancer Metastasis Rev. 2022 Mar;41(1):147-172. doi: 10.1007/s10555-022-10019-5. Epub 2022 Jan 12.
2
Anticoagulation therapy in non-valvular atrial fibrillation in the COVID-19 era: is it time to reconsider our therapeutic strategy?新冠疫情时代非瓣膜性心房颤动的抗凝治疗：是时候重新审视我们的治疗策略了吗？
Eur J Prev Cardiol. 2022 Nov 8;29(15):2069-2071. doi: 10.1093/eurjpc/zwab021.
3
Multidisciplinary Approach to the Diagnosis and In-Hospital Management of COVID-19 Infection: A Narrative Review.COVID-19感染的诊断与住院管理的多学科方法：一项叙述性综述
Front Pharmacol. 2020 Dec 9;11:572168. doi: 10.3389/fphar.2020.572168. eCollection 2020.
4
Core-Shell Eudragit S100 Nanofibers Prepared via Triaxial Electrospinning to Provide a Colon-Targeted Extended Drug Release.通过同轴静电纺丝制备的核壳型聚丙烯酸树脂S100纳米纤维用于结肠靶向的长效药物释放。
Polymers (Basel). 2020 Sep 7;12(9):2034. doi: 10.3390/polym12092034.

本文引用的文献

1
Primary prevention efforts are poorly developed in people at high cardiovascular risk: A report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries.在心血管疾病高危人群中，初级预防工作开展得很差：来自欧洲心脏病学会 EURObservational Research Programme EUROASPIRE V 调查的 16 个欧洲国家的报告。
Eur J Prev Cardiol. 2021 May 8;28(4):370-379. doi: 10.1177/2047487320908698. Epub 2020 Mar 20.
2
Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study.利伐沙班联合阿司匹林用于心血管疾病患者的缺血性事件预防：一项成本效益研究。
Eur J Prev Cardiol. 2020 Sep;27(13):1354-1365. doi: 10.1177/2047487320913380. Epub 2020 Mar 29.
3
Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19).COVID-19 患者的致命结局对心血管的影响。
JAMA Cardiol. 2020 Jul 1;5(7):811-818. doi: 10.1001/jamacardio.2020.1017.
4
Effectiveness of comprehensive cardiac rehabilitation in coronary artery disease patients treated according to contemporary evidence based medicine: Update of the Cardiac Rehabilitation Outcome Study (CROS-II).基于当代循证医学治疗的冠心病患者综合心脏康复的疗效：心脏康复结局研究（CROS-II）更新。
Eur J Prev Cardiol. 2020 Nov;27(16):1756-1774. doi: 10.1177/2047487320905719. Epub 2020 Feb 23.
5
Chronic medication intake in patients with stable coronary heart disease across Europe: Evidence from the daily clinical practice. Results from the ESC EORP European Survey of Cardiovascular Disease Prevention and Diabetes (EUROASPIRE IV) Registry.欧洲稳定型冠心病患者的慢性药物治疗：来自日常临床实践的证据。ESC EORP 欧洲心血管疾病预防和糖尿病调查（EUROASPIRE IV）登记处的结果。
Int J Cardiol. 2020 Feb 1;300:7-13. doi: 10.1016/j.ijcard.2019.09.015. Epub 2019 Sep 7.
6
Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry.27 个国家的冠心病患者生活方式及对心血管危险因素控制的影响：欧洲心脏病学会 ESC-EORP EUROASPIRE V 注册研究结果。
Eur J Prev Cardiol. 2019 May;26(8):824-835. doi: 10.1177/2047487318825350. Epub 2019 Feb 10.
7
Impact of Tobacco Versus Electronic Cigarette Smoking on Platelet Function.烟草与电子烟吸烟对血小板功能的影响。
Am J Cardiol. 2018 Nov 1;122(9):1477-1481. doi: 10.1016/j.amjcard.2018.07.029. Epub 2018 Aug 3.
8
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.利伐沙班联合或不联合阿司匹林治疗稳定的外周动脉或颈动脉疾病患者：一项国际、随机、双盲、安慰剂对照试验。
Lancet. 2018 Jan 20;391(10117):219-229. doi: 10.1016/S0140-6736(17)32409-1. Epub 2017 Nov 10.
9
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.利伐沙班联合或不联合阿司匹林用于稳定型心血管疾病。
N Engl J Med. 2017 Oct 5;377(14):1319-1330. doi: 10.1056/NEJMoa1709118. Epub 2017 Aug 27.
10
Substantial improvement of primary cardiovascular prevention by a systematic score-based multimodal approach: A randomized trial: The PreFord-Study.系统评分多模式方法对一级心血管预防的显著改善：一项随机试验：PreFord 研究。
Eur J Prev Cardiol. 2017 Sep;24(14):1544-1554. doi: 10.1177/2047487317718081. Epub 2017 Jul 10.